Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

Next Previous
X
Search
Trial Profile

A Study To Evaluate The Efficacy Of Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy To Reduce Provoked Allergic Rhinitis Symptoms Using The Nasal Allergen Challenge Model

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LIBERTY Grass AID
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 18 Nov 2021 Results (n=52) assessing pharmacokinetics of functional serum dupilumab and concentration response relationships published in the Journal of Clinical Pharmacology
    • 26 Jun 2019 Status changed from recruiting to completed.
    • 05 Oct 2018 Planned End Date changed from 4 Jun 2019 to 24 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top